Monoclonal Gammopathy of Undetermined Significance
Bibliography
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer, Lyon, 2008
- Warnke RA, Weiss LM, Chan JKC, Cleary ML, Dorfman RF . Tumors of the Lymph Nodes and Spleen, Atlas of Tumor Pathology, AFIP Third Series, Fascicle 14, 1995
- Blade J, M. Dimopoulos, L. Rosinol, S. V. Rajkumar, and R. A. Kyle. Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations J. Clin. Oncol., February 1, 2010; 28(4): 690 - 697.
- Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res. 2007 Apr;149(4):231-5.
- Perez-Persona E et al, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering mutliple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007 Oct 1;110(7):2586-92.
- Raja KR, Kovarova L, Hajek R.Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol. 2010 Mar 1. [Epub ahead of print]
- Van Camp B, Durie BG, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan TM. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56. Blood. 1990 Jul 15;76(2):377-82.
